Clinical trial · Interventional
Effect of Honey For CIN II
The Effect of Medical Grade Honey (L-Mesitran) for Cervical Intraepithelial Neoplasia-II
NCT06219018CI-TRIAL-00091169HoneyForCINIIrecruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase in the normalization of CIN II lesions compared to expectant management.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Intraepithelial Neoplasia-II | — | UNRESOLVED | — |
| High Risk Human Papillomavirus | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Medical grade honey formulation (MGH) (L-Mesitran®) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Medical grade honey formulation (MGH) (L-Mesitran®) for CIN II
- description
- Daily application of 5 grams (with applicator) for 3 months. Then weekly application (5 grams with applicator) for 3 months.
- interventionNames
- Drug: Medical grade honey formulation (MGH) (L-Mesitran®)
Primary outcomes (1)
- measure
- Clearance of hr-HPV
- timeFrame
- 6 months
- description
- The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus
Secondary outcomes (6)
- measure
- Regression of CIN II
- timeFrame
- 12-24 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Women 18-40 years * Primary CIN II confirmed histologically in the biopsy on colposcopic examination * Sufficient mastery of the Dutch language Exclusion Criteria: * Simultaneous abnormality in columnar epithelial cells (AIS). * Hr-HPV negative cytology * Immunosuppressant use/Autoimmune disease (HIV, CVID) * History of cervical carcinoma or previous treatment for CIN (LLETZ or imiquimod) * Pregnancy or the intention to become pregnant during the study period * Legal incompetence * Known allergies to honey
References
Publications (1)
- DERIVEDProp J, De Vos van Steenwijk P, Lardenoije CMJG, Cremers NAJ, Morre SA, Mongula J. Effect of medical-grade honey (L-Mesitran) for cervical intraepithelial neoplasia II: protocol for a multicentre cohort pilot study (HONEY FOR CIN II study). BMJ Open. 2025 Jul 24;15(7):e104585. doi: 10.1136/bmjopen-2025-104585. PMID 40707147